Furthermore, the forced expression of C/EBPβ or MYB in all cases was shown to counteract the anti-proliferative effects of the compounds, strongly suggesting that the inhibition of a common function of MYB and C/EBPβ underlies their activity in AML cells [66,83]. The gene discussed is MYB; the disease is acute myeloid leukemia.